Foventa Therapeutics
PrivateLast Round
Series A
Sep 1, 2026
Total Funding Raised
$11.17M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Foventa Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Series A round in January 2019.
Foventa Therapeutics is a biopharmaceutical company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Foventa Therapeutics Comparables
Compare Foventa Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PanOpttica | 88% | |
| D-Sight | 82% | |
| Retinset, S.L. | 82% |
For institutional investors. Book with your work email.
Foventa Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 1, 2026 | ||||
| Series A | Jan 3, 2019 | ||||
| Grant | Feb 6, 2017 | ||||
| Angel | Dec 1, 2016 | ||||
| Angel | Oct 5, 2015 | ||||
Seed | Apr 3, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Foventa Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ACF Investors | Angel, Series A |
| IP Group | Seed |
| o2h ventures | Angel, Series A |
| University of Bristol Enterprise Fund | Angel, Series A |
| Uniseed | Angel, Series A |
| Parkwalk Advisors | Angel, Series A |
| Wren Capital | Angel, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 1, 2026
Completed a Series A funding round.
- Jun 22, 2026
Monthly visitors increased 58% MoM.
For institutional investors. Book with your work email.
Foventa Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Foventa Therapeutics's valuation, stock price, and market status.
Is Foventa Therapeutics a public or private company?
Foventa Therapeutics is a private company.
What is the current stock price of Foventa Therapeutics?
Foventa Therapeutics is a private company, so its shares have no public market price. Caplight tracks Foventa Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Foventa Therapeutics worth (valuation)?
Valuation information for Foventa Therapeutics is not publicly available.
Can I buy Foventa Therapeutics stock?
Foventa Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Foventa Therapeutics's last funding round?
Foventa Therapeutics's most recent funding round was Series A on September 1, 2026.
Who are the main investors in Foventa Therapeutics?
Key investors in Foventa Therapeutics include Wellcome Trust.
Will Foventa Therapeutics IPO soon?
No public IPO plans have been announced for Foventa Therapeutics.
How can I track Foventa Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Foventa Therapeutics's shares on secondary markets.